1022 results about "Osteocyte" patented technology

The invention provides a tripeptide for promoting bone growth, the tripeptide is VPF, the amino acid sequence of the tripeptide is Val-Pro-Phe, the molecular weight of the tripeptide is 361.44 Da, and the tripeptide belongs to the technical field of functional bioactive peptides. The tripeptide can be prepared from egg yolk protein through enzymolysis separation and purification, can also be obtained through chemical solid-phase synthesis, has a good effect of promoting bone growth, can remarkably improve the growth and proliferation level of osteoblasts in a body, promotes synthesis and secretion of bone matrixes, and has a good application prospect. Meanwhile, the secretion of insulin-like growth factors (IGF-1), transforming growth factors (TGF-beta1) and I-type procollagen amino-terminal peptide (PINP) in the body is efficiently promoted, and good market prospects are achieved.

The invention provides a bacterial strain for improving bone health and application of the bacterial strain. The preservation number of bifidobacterium animalis subsp. Lactis BL-11 is CGMCC (China General Microbiological Culture Collection Center) No.20847. The strain can promote osteoblasts and inhibit osteoclasts in a cell experiment; by constructing a mouse model with abnormal bone growth, the BL-11 probiotics have an obvious improvement effect on bone development indexes of the model mouse, promote bone formation and inhibit bone resorption; furthermore, the BL-11 probiotics can improve the ostealgia score, life quality and bone mineral density of people with osteoporosis or bone mass reduction. The results indicate the application potential of the probiotics in improvement of abnormal bone growth and prevention and treatment of osteoporosis.

The invention belongs to the technical field of hydrogel, and relates to piezoelectric / conductive integrated hydrogel for jaw defect repair, which is prepared from methylacryloyl protein, zwitterionic monomer and titanate piezoelectric particles through ultraviolet crosslinking under the action of a crosslinking agent and a photoinitiator, the hydrogel comprises, by mass, 1.0%-10% of methacrylated protein, 1.0%-10% of zwitterionic monomers, 1.0%-10% of titanate piezoelectric particles and 0.1%-5% of an initiator, and the volume fraction of an accelerant is 0.05%-1.0%. The hydrogel disclosed by the invention has excellent mechanical strength and certain flexibility, can realize piezoelectric and conductive functions of the hydrogel, can effectively promote proliferation, differentiation and mineralization of bone cells under the action of an electric field, accelerates bone tissue repair, and has a more remarkable bone regeneration effect compared with a non-electrical stimulation material in the prior art.

The invention relates to the technical field of biological medicines, and provides application of an ADRM1 inhibitor in preparation of a medicine for treating osteoporosis. Through the scheme of the invention, the ADRM1 affects bone metabolism, bone tissue morphological structure and osteoporosis progress, and can provide a new drug target for clinical prevention and treatment of osteoporosis. The ADRM1 inhibitor is applied to preparation of the osteoporosis medicine, and bone mass loss can be obviously reduced by down-regulating ADRM1 expression or inhibiting ADRM1 activity and inhibiting differentiation and functions of osteoclasts, so that the effect of treating osteoporosis is achieved.

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The invention provides an application of bifidobacterium animalis subsp. Lactis CP-9 in preparation of a product for promoting bone growth and development or improving bone health. Long-term research and a large number of experiments show that the bifidobacterium animalis subsp. Lactis CP-9 can improve the bone volume fraction, the bone trabecula thickness, the bone density and the bone volume of an organism, and can also effectively improve the growth hormone level and the insulin-like growth factor 1 level, so that bone growth and development are promoted. Meanwhile, the bifidobacterium animalis subsp. Lactis CP-9 can effectively improve the N-terminal propeptide level, osteocalcin level, bone morphogenetic protein level and osteoprotectin level of I-type procollagen in a body, and remarkably reduce the amino-terminal peptide level of the I-type collagen and the ligand level of nuclear factor kappa B receptor activating factor, so that osteoblast differentiation is promoted, osteoclast differentiation is inhibited, and osteoclast differentiation is inhibited. Furthermore, bone formation is promoted, bone resorption is inhibited, bone metabolism is improved, and finally the effect of improving bone health is achieved.

The invention provides a tetrapeptide for promoting bone growth, the amino acid sequence of the tetrapeptide is Glu-Pro-Gly-Phe (EPGF), the molecular weight of the tetrapeptide is 448.48 Da, the tetrapeptide can be prepared from egg yolk protein through protease enzymolysis, separation and purification and can also be obtained through chemical solid-phase synthesis, and the tetrapeptide belongs to the technical field of functional bioactive peptides. The tetrapeptide prepared by the invention can promote the growth of osteoblasts in a body and improve the secretion level of insulin-like growth factor-1 (IGF-1), transforming growth factor-beta1 (TGF-beta1) and I-type procollagen amino terminal peptide (PINP) in cells, so that the effect of promoting bone growth is achieved, and a new functional component is provided for a product for improving bone growth.

The invention provides a bone organ model as well as a construction method and application thereof, and the method comprises the following steps: arranging a biological material with a micropore array in a cell culture plate to obtain a bone organ chip; suspending the initial stem cells in a culture medium, and promoting the cells to form a spherical structure through cell aggregation or by using a non-adhesive culture surface, so as to obtain cell spheres; and culturing the cell spheres in the bone organ chip by adopting the culture medium for constructing the bone organ model to obtain the bone organ model. The skeletal organ is successfully constructed through in-vitro self-organized 3D co-culture initial stem cells including embryonic stem cells, induced pluripotent stem cells, bone marrow mesenchymal stem cells, osteoblasts, bone cells, all levels of osteogenic precursor cells, osteogenic-like cells and MC3T3-E1 cells, and the skeletal organ can become an important tool for researching and treating bone related diseases.

Provided are compositions comprising a HKUOT-S2 protein, at least one peptide according to at least one of SEQ ID NO: 81-97, or a protein comprising an amino acid sequence according to at least one of SEQ ID NO: 81-97. Methods of osteogenesis are provided, including, for example, methods of enhancing bone repair, modulating polarization of macrophages with proinflammatory and anti-inflammatory activity and bone resorption of osteoclasts, and methods of treating inflammatory diseases, spinal cord injury, liver and kidney diseases, cardiovascular diseases, diabetes, post-menopausal syndrome, infertility, or hematopoietic diseases, or enhancing wound healing.

The invention discloses a preparation method and application of high-strength, high-inorganic-ratio and degradable organic-inorganic composite hydrogel, and belongs to the technical field of biomedical tissue engineering. The hydrogel is prepared from the following components in percentage by weight: 30 to 70 percent of calcium phosphate nano-cluster and 30 to 70 percent of sodium alginate. The organic-inorganic composite hydrogel is beneficial to proliferation and mineralization of bone cells, and more ideal bone guidance is realized. Experimental results prove that the material has good cytocompatibility, can quickly promote rat skull defect repair (8 mm limit bone injury repair time is shortened to 4 weeks), and has a more remarkable healing effect compared with a contrast autogenous bone graft material with an optimal clinical repair effect. The high-strength organic-inorganic composite hydrogel prepared by the invention is of a single-network structure, shows good mechanical properties, also has excellent degradability matched with tissues, and is beneficial to hard tissue repair.

The invention belongs to the technical field of biological coatings, and provides an antibacterial coating with a TaCu nano multilayer structure and a preparation method of the antibacterial coating. The antibacterial coating comprises a Cu layer and a Ta layer which are sequentially and alternately stacked on a base body, the Cu layer is in contact with the base body, and the Ta layer is the outermost layer. The Cu layers and the Ta layers are sequentially and alternately stacked on the substrate, the Cu < 2 + > layer-by-layer release delays the release rate, the cytotoxicity is reduced, and a lasting antibacterial effect is obtained; meanwhile, due to introduction of Ta, the osteogenesis performance of the matrix is effectively enhanced, and proliferation of bone cells is promoted. The antibacterial coating does not show cytotoxicity to rat bone marrow mesenchymal stem cells, can inhibit growth of staphylococcus aureus for a long time, is beneficial to promoting proliferation of osteoblasts, and can be used as an antibacterial coating for the surface of a bone implant. The preparation method of the antibacterial coating provided by the invention has the advantages of simple process, high deposition speed and high bonding strength.

The invention belongs to the field of biological medicines, and discloses an application of Akkermansia muciniphila or an extracellular vesicle of the Akkermansia muciniphila in preparation of a medicine for alleviating the ischemic necrosis of the alcoholic femoral head. Based on the pathogenesis characteristics of the AIONFH, the Akk bacteria and the extracellular vesicles thereof are used for treating the AIONFH for the first time, the molecular mechanism of the Akk bacteria and the extracellular vesicles thereof for regulating and controlling the intestinal tract-skeleton axis function, inhibiting bone cell apoptosis and improving the bone trabecula microstructure is deeply researched, the anti-pressure ability of bone tissue is improved, and the research blank in the field is filled. Compared with a traditional treatment method, the osteonecrosis pathological change is improved through a single way, and a novel multi-target treatment strategy is provided from multiple aspects of regulating inflammatory response, recovering bone metabolism balance, promoting intraosseous blood supply and the like.

The invention provides a composition of a salvianolic acid extract and a tanshinone extract as well as a preparation method, application and a product of the composition, and belongs to the field of medicines. The preparation method of the composition of the salvianolic acid extract and the tanshinone extract comprises steps 1)-4). The composition with carbonic anhydrase inhibitory activity is obtained by extracting the salvianolic acid extract and the tanshinone extract from the radix salviae miltiorrhizae and mixing the salvianolic acid extract and the tanshinone extract, the composition can achieve synergistic interaction, and reference is provided for research and development and component compatibility of medicines mainly comprising the radix salviae miltiorrhizae. The composition provided by the invention can be used for reducing intraocular pressure, inducing diuresis, correcting metabolic acidosis, increasing vascular oxygen flux, improving pulmonary ventilatory capacity, expanding cerebral vessels, inducing tumor cell apoptosis and inhibiting osteoclast bone resorption; the traditional Chinese medicine composition can be used for treating or preventing diseases with intraocular hypertension as symptoms, cardiac edema or acute altitude sickness, cardiovascular and cerebrovascular diseases and bone metabolism diseases caused by osteoporosis.

The invention relates to the technical field of medical instruments, in particular to an electromagnetic ultrasonic device for treating osteoporosis, which comprises a bed body, an electromagnetic ultrasonic probe, a data acquisition module, a data processing module and an artificial intelligence analysis module, an ultrasonic treatment assembly and an electromagnetic treatment assembly are integrated in the electromagnetic ultrasonic probe; the ultrasonic treatment assembly emits ultrasonic waves and transmits the ultrasonic waves to bones through soft tissues for ultrasonic treatment; the electromagnetic treatment assembly generates an alternating electromagnetic field to stimulate bone cells; physiological signal data are analyzed in real time through an artificial intelligence algorithm, physiological state changes are predicted, output parameters of PEMF and LIPUS are automatically adjusted to adapt to individual physiological differences, and personalized treatment is achieved.

Orthopedic implants, particularly interbody spacers, have a combination of correct pore size and stiffness / flexibility. When the implants have the proper pore size and stiffness, osteocytes are able to properly bridge the pores of the implant and then experience a proper compressive load to stimulate the bone cells to form bone within the pores. An implant includes a body formed of an osteoconductive material and having a stiffness of between 400 megapascals (MPa) and 1,200 MPa. Additionally, the body includes a plurality of pores having an average size of between 150 microns and 600 microns. The pores permit the growth of bone therein. The body is formed of packs of coils which may be formed using an additive manufacturing process and using traditional orthopedic implant materials such as titanium and titanium alloys while still achieving desired stiffness and pore sizes of the implants.

The invention discloses a method and a device for acquiring parameters of an internal fracture fixation system, and relates to the technical field of medical data processing. Constructing a digital model of the skeleton and the surrounding soft tissue based on the three-dimensional scanning image by utilizing a biomechanical principle; using a machine learning algorithm to train the historical case data, and generating a preliminary internal fixed parameter prediction model; applying the preliminary parameters to a digital model for simulation verification, and optimizing the internal fixed parameters to an optimal combination; performing personalized adjustment on the simulation result according to individual differences of patients and experience of clinical doctors; the state of the internal fixation system is monitored in real time in the operation process, and parameter fine adjustment is conducted according to feedback; the fracture healing condition is regularly evaluated after the operation, and the internal fixation parameters are adjusted according to the evaluation result. Through personalized and precise internal fixation parameter setting, a good mechanical repair environment is created for a fracture part, bone cell proliferation and ordered growth of callus are promoted, and the healing time is effectively shortened.

A method for constructing a microfluidic bone organoid-on-chip can continuously observe the impacts of different external factors on a bone tissue structure based on the “ternary regulation theory” of bone angiogenesis-bone resorption-osteogenesis coupling. The method includes: (1) building a visual three-dimensional cell cultivation platform to continuously observe impacts of different external factors on a ternary regulation theory based on angiogenesis of osteoclast precursors, osteoblasts and osteoclasts, such that a user is allowed to directly observe interactions among various kinds of cells; (2) designing microfluidic channels in a chip to allow a reagent involved to present a concentration gradient distribution in the chip; and (3) adding three bioinks including osteoblasts, osteoclasts and vascular endothelial cells respectively, so as to reflect the three cell components individually, in pairs, and as a whole in the chip. An apparatus for constructing a microfluidic bone organoid-on-chip is further provided.

The invention relates to a drug delivery system for treating osteoporosis caused by cell aging as well as a preparation method and application of the drug delivery system. The drug delivery system comprises a bone targeting ligand modified drug carrier and an anti-bone cell aging drug entrapped in the drug carrier, the bone targeting ligand is selected from any one of alendronate sodium, bisphosphate and analogues thereof, tetracycline, tartrate-resistant acid phosphatase TRAP binding peptide, pregnancy region protein or e-selectin; the anti-osteocyte senescence medicine comprises any one or a combination of at least two of dasatinib, quercetin, metformin, L-ascorbic acid, aspirin or fisetin. According to the prepared drug delivery system, the bioavailability of the drug can be effectively improved, targeted release of the drug in bone tissue is achieved, senescent cell enrichment is reduced, and the bone microenvironment is improved, so that a new strategy is provided for treating osteoporosis caused by cell senescence.

The invention discloses an artificial bone for promoting osteoporotic bone defect repair and a preparation method thereof, and belongs to the technical field of biomedical materials. The artificial bone disclosed by the invention is prepared by compounding the following components in percentage by weight: 89.65 to 89.85 weight percent of polylactic acid-glycolic acid copolymer, 9.85 to 10.15 weight percent of nano hydroxyapatite and 0.1 to 0.5 weight percent of zoledronic acid. In the artificial bone, the nano-hydroxyapatite and zoledronic acid are uniformly dispersed in the polylactic acid-glycolic acid copolymer, and the porous structure on the surface of the artificial bone is combined, so that osteoblasts can be attached to the surface of the artificial bone, and new bone tissues can grow in the artificial bone; phosphonate radicals of zoledronic acid can be chelated with nano-hydroxyapatite to generate stable chemical bonds, the stable chemical bonds are introduced into the polylactic acid-glycolic acid copolymer, effective loading of zoledronic acid can be achieved, and the effective loading of zoledronic acid can inhibit bone resorption increase caused by overactivation of osteoclasts and repair osteoporotic bone defects.

The invention discloses combined lactobacillus salivarius CCFM1327 capable of inhibiting foaming of macrophages and relieving periodontitis, and belongs to the technical field of microorganisms. According to the invention, the strain of combined lactobacillus salivarius CCFM1327 is obtained, and the combined lactobacillus salivarius has the effects of inhibiting foaming of macrophages and relieving periodontitis, which are specifically reflected in that the combined lactobacillus salivarius can inhibit foaming of RAW264.7 cells caused by ox-LDL; the growth of porphyromonas gingivalis can be effectively inhibited; the periodontal probing and diagnosing depth of the periodontitis rats can be obviously reduced; the number of pathogenic bacteria in the oral cavity of the periodontitis rat is reduced; the level of an inflammatory factor IL-17A in serum is reduced; alveolar bone loss of rats suffering from periodontitis is reduced; and the number of alveolar bone osteoclasts is reduced.

The invention discloses a medicine for treating osteoarthritis, and belongs to the field of medicine, the medicine comprises a reagent capable of stimulating chondrocyte development, and the medicine L-arginine can promote expression of chondrocyte anabolic factors and reduce expression of cartilage degradation markers, so that chondrocytes are protected to a certain extent; in addition, the medicine provided by the invention has an excellent cartilage repair function, can inhibit the progress of degenerative osteoarthritis, has good biocompatibility, and has no cytotoxicity to cartilage cells.

The invention discloses a calcium-containing antarctic krill oligopeptide nutritional composition for promoting bone cell growth and application thereof, and belongs to the technical field of functional foods.The calcium-containing antarctic krill oligopeptide nutritional composition is composed of antarctic krill oligopeptide and a calcium compound, and the mass ratio of the antarctic krill oligopeptide to the calcium compound is (0.5-5): 1; or the composition is composed of the euphausia superba oligopeptide, the calcium compound and the vitamin D, and the mass ratio of the euphausia superba oligopeptide to the calcium compound to the vitamin D is (0.5-5): 1: (2.5 * 10 <-5 >)-(15 * 10 <-5 >); the mass of the calcium compound is calculated according to the content of the calcium element in the antarctic krill oligopeptide; the antarctic krill oligopeptide is obtained by treating antarctic krill, antarctic krill powder or defatted antarctic krill powder by utilizing an enzymolysis method; the content of a peptide fragment with the molecular weight of less than 1000Da in the antarctic krill The raw materials of the nutritional composition are easy to obtain, the safety is high, and the nutritional composition can be used for preparing products with the effect of promoting bone cell growth.

The invention belongs to the field of medicines, and particularly relates to application of a new target NCSTN for regulating and controlling bone metabolism and an agonist of the new target NCSTN in preparation of a medicine for preventing or treating osteoporosis. The invention aims to provide a new target NCSTN for regulating and controlling bone metabolism and application of the new target NCSTN in promoting osteogenic activity, inhibiting osteoclast activity and treating osteoporosis. According to the invention, the mechanism of the NCSTN agonist for treating osteoporosis is found for the first time, and the NCSTN agonist has the effects of inhibiting osteoclast maturation and differentiation and promoting osteoblast bone formation function. The mechanism is greatly different from the previously reported mechanism of singly inhibiting bone resorption or singly promoting bone formation, and the osteoporosis treatment which simultaneously acts on bone resorption and bone formation can greatly reduce the adverse reaction of the body to the medicine.

The invention relates to the field of application of medicines for treating rheumatoid arthritis, and discloses an application method of targeted MTHFD2 in preparation of medicines for treating bone destruction of rheumatoid arthritis, (1) the level of MTHFD2 in knee joints of rheumatoid arthritis patients and mice is increased; (2) the expression of MTHFD2 is up-regulated in the process of differentiating osteoclast precursor cells from mice and humans into osteoclasts; (3) the MTHFD2 inhibitor can significantly inhibit differentiation of osteoclasts from mice and humans; (4) MTHFD2 gene silencing can inhibit differentiation of mouse-derived osteoclasts, MTHFD2 gene overexpression can promote differentiation of osteoclasts, and reliability of MTHFD2 as a therapeutic target is verified; and (5) the MTHFD2 inhibitor can improve the bone destruction of arthritis mice and increase the bone tissue density, which prompts that the targeted MTHFD2 is useful for the treatment or prevention of rheumatoid arthritis and other diseases.

The invention relates to an application of a CTHRC1 inhibitor in preparation of a medicine for preventing and / or treating arthritis. Specifically, the invention provides application of an inhibitor or an antagonist of a CTHRC1 gene or a protein thereof, the inhibitor or the antagonist is used for preparing a composition or a preparation, and the composition or the preparation is used for (a) preventing and / or treating arthritis-related diseases; and / or (b) inhibiting cartilage cell senescence.

The invention relates to the technical field of medicine, in particular to application of beta-hydroxybutyric acid in preparation of medicine for preventing and / or treating osteoporosis, the osteoporosis comprises postmenopausal osteoporosis and diabetic osteoporosis due to estrogen deficiency, the administration concentration of the beta-hydroxybutyric acid is 150mM, and the administration concentration of the beta-hydroxybutyric acid is 10mM. According to the application of the beta-hydroxybutyric acid in preparing the medicine for inhibiting osteoclast differentiation or osteoclast formation, the beta-hydroxybutyric acid inhibits osteoclast precursor cells from being differentiated into osteoclasts, and the administration concentration of the beta-hydroxybutyric acid is 10 mM; the invention proves that the beta-hydroxybutyric acid improves bone microstructures of OVX mice and db / db mice, inhibits osteoclast differentiation and reduces bone resorption, and provides a new target for prevention and treatment of osteoporosis.

The invention discloses an oral tooth implantation structure and method, and particularly relates to the technical field of dental implants.The oral tooth implantation structure comprises an implant and an abutment, external threads are arranged on the periphery of the implant, and a first mounting hole is formed in the top of the implant. According to the oral tooth implantation structure and method, through mutual cooperation of the extrusion assembly, the sealing assembly and the fixing bolt piece, the bone meal gel is extruded and filled into a gap between the implant and the implantation hole through the second through hole, and the bone meal gel can increase the bone mass around the implant and stimulate bone cell proliferation, so that the implantation effect is improved; according to the utility model, by arranging the locking component, the formation of a new bone is promoted, the implant is tightly combined with a surrounding skeleton structure, so that the connection strength of the implant and an alveolar bone is greatly increased, and meanwhile, the arranged locking component can effectively prevent relative rotation between the fixing tube and the implant, so that relative rotation between the abutment and the implant is prevented; therefore, loose connection between the abutment and the implant caused by looseness of the fixing bolt piece is avoided.

The invention discloses a yak bone collagen peptide for improving osteoporosis and preparation and application thereof, and relates to the field of biological medicine, the yak bone collagen peptide comprises collagen peptide with the molecular weight of 500-2000 Daltons, contains a glycine-proline-hydroxyproline tripeptide core structure, can promote osteoblast differentiation and inhibit osteoclast activity, and can be used for treating osteoporosis. The amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine, and the amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine; and the amino acid is glycine, proline, hydroxyproline, serine, leucine and alanine. The yak bone collagen peptide has a unique glycine-proline-hydroxyproline tripeptide structure, the molecular weight is controlled within the range of 500-2000 Daltons, the structure can promote osteoblast differentiation and inhibit osteoclast activity at the same time, and the problem that a traditional osteoporosis treatment medicine is single in function is solved.

The invention discloses a method for inducing osteoblasts by using mesenchymal stem cells, and belongs to the technical field of biology. The method for inducing the osteoblasts comprises the step of adding brucella outer membrane protein into a conventional osteoblast induction culture medium to promote the dental pulp stem cells to be differentiated into the osteoblasts. According to osteoblast differentiation metaphase differentiation marker detection, the cell ALP activity of a group added with 800ng / mL of brucella outer membrane protein is 2.36 times that of a conventional osteoblast induction culture medium group; according to osteoblast differentiation end-stage differentiation marker detection, the calcium deposition amount of brucella outer membrane proteome cells added with 800ng / mL is 481.54 mu g / mg protein, and is 2.55 times of that of a conventional osteoblast induction culture medium group. By adding the brucella outer membrane protein into a conventional osteoblast induction culture medium, the osteogenic differentiation efficiency of the dental pulp stem cells can be effectively improved.

The invention discloses magnesium-containing mesoporous active bioglass with drug sustained release, immunoregulation and bone metabolism regulation effects and application thereof. The drug-loaded MBGN is prepared by doping Mg ions and loading drugs, and the drug-loaded MBGN has good biocompatibility and can be decomposed in an acid environment to achieve controllable slow release of the drugs; on the other hand, released ions such as Si, Ca and Mg have a certain immunoregulation function, polarization of macrophages from M1 type to M2 type is promoted, inflammatory response is reduced, differentiation and maturation of osteoclasts are inhibited, and meanwhile, the released ions and drugs carried in mesopores play a synergistic effect, so that a good treatment effect is achieved. The drug-loaded MBGN provided by the invention has various biological properties, can overcome the defects of low drug loading rate, insufficient anti-inflammatory effect and the like when the existing mesoporous bioactive glass material is applied clinically, and has a good application prospect.